Cipla To Pour $460 Million Into Production Expansion In India
This article was originally published in PharmAsia News
Executive Summary
India's Cipla says it plans to invest nearly $460 million during the next two years as part of its expansion policy to produce more drugs for domestic and foreign consumption. The funds are to be added to a program already building new facilities and expanding others to take advantage of an anticipated 12 percent to 15 percent growth next year. Part of that growth is expected to be generated by a 10 percent growth in company exports, already comprising half of its business. (Click here for more
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.